Merck, a big medicine company, had a bit of a rough end to 2024. Their sales went up a little, but not as much as people hoped. Some of their medicines didn't sell as well as expected, especially in China.
- Keytruda, a cancer medicine, is still doing well, but might face competition soon.
- Gardasil, a vaccine, had lower sales, mostly because of problems in China.
- Merck's overall stock price dropped 16% this year.
| Item | Fact/Prediction |
|---|---|
| Merck's Stock | Down 16% in 2025 |
| Keytruda Sales | Up 19% in 2024, but future uncertain |
| Gardasil Sales | Down 17% in Q4 2024, China market weak |
